GET DAILY SIGNALSAbbVie (ABBV) Advances +7% on Solid Q3 Results and Guidance Lift
Key Takeaways
- AbbVie shares have advanced roughly 7% over the past month, supported by a third-quarter earnings beat and an upward revision to full-year guidance.
- Third-quarter 2026 revenue rose about 10% to $17.4 billion, while adjusted earnings per share of $3.82 exceeded the company's guidance midpoint.
- Skyrizi and Rinvoq, the company's newer immunology medicines, each grew more than 20% and are more than offsetting Humira's biosimilar-driven decline.
- Management raised full-year revenue guidance to approximately $67.8 billion and adjusted EPS guidance to $13.95–$13.99.
- AbbVie announced a 5.2% dividend increase to $1.82 per share, reinforcing its reputation as a dividend-growth name.
- For deeper data, explore AbbVie's Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are positioned across the market by exploring Trending AI Robots.
Market Snapshot for ABBV
AbbVie Inc. (ABBV) has shown a modestly positive tone over the past month. Shares moved from the low-$270s in early October to around $291 in recent trading. The gains stem mainly from a strong third-quarter earnings report and the accompanying increase in full-year guidance rather than any single dramatic event. Broader sentiment in large-cap pharmaceuticals has stayed constructive, and ABBV's mix of double-digit growth in key products plus a rising dividend continues to draw attention from both growth and income investors.
Business Overview and Competitive Standing
AbbVie operates as a global research-based biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, oncology, neuroscience, and aesthetics. Its primary growth engines remain Skyrizi and Rinvoq, which address inflammatory and autoimmune conditions such as psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. The company also offers Botox and Juvederm in aesthetics, Vraylar along with Ubrelvy and Qulipta for neuroscience, and Venclexta and Imbruvica in oncology.
Over recent years ABBV has managed the loss of exclusivity on Humira by building a broader portfolio of newer medicines with extended patent life. Strengths include substantial commercial reach in immunology, an expanding pipeline, and robust free-cash-flow generation that supports dividend increases and selective acquisitions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Drivers Behind the Stock Move
The third-quarter 2026 results, released in late October, provided the main support for the recent price action. Revenue climbed about 10% to $17.4 billion and beat expectations, while adjusted EPS of $3.82 came in $0.07 above the midpoint of guidance. Immunology revenue approached $9.2 billion with 16.6% operational growth. Skyrizi delivered nearly $5.8 billion, up 22.9% operationally, and Rinvoq rose 24.3% to $2.7 billion—more than offsetting Humira’s 30.6% drop.
Management increased full-year revenue guidance by $200 million to roughly $67.8 billion and raised adjusted EPS guidance to $13.95–$13.99, marking the third revenue upgrade of the year. The quarterly dividend was lifted 5.2% to $1.82 per share. Additional updates included FDA approval of Skyrizi subcutaneous induction for Crohn’s disease, approval of Juvmo for Parkinson’s disease, and completion of the Apogee Therapeutics acquisition, which brings the atopic dermatitis candidate zumilokibart into the pipeline.
2026 Outlook and Areas to Monitor
Looking forward, the key question remains whether Skyrizi and Rinvoq can maintain their growth trajectory through 2026 and beyond as immunology competition increases. Attention will focus on new indication launches, including Rinvoq’s expected U.S. approvals for vitiligo and alopecia areata, plus the rollout of Skyrizi’s subcutaneous induction in Crohn’s disease. In neuroscience, early commercialization of Juvmo and ongoing growth from Vraylar and the oral CGRP migraine products will be important to track.
Macro and policy factors, such as U.S. drug-pricing changes under the Inflation Reduction Act and reimbursement trends, stay relevant. The aesthetics business, which has faced softer demand, and the oncology portfolio, impacted by Imbruvica’s decline, will also warrant watching for stabilization signs. Strong free cash flow and pipeline progress give some visibility, though clinical and regulatory outcomes still carry uncertainty. I’m watching this closely as the year progresses.
Exploring Automated Trading Strategies
Tickeron’s Trending AI Robots page highlights some of the platform’s stronger-performing AI trading bots. While hundreds of bots are available that cover thousands of tickers, only the most relevant and top-performing strategies appear here. Approaches range from short-term momentum models to longer-term trend-following systems, allowing investors to review options that fit different risk levels and time horizons. I find it useful to browse this section periodically to see how automated systems are positioned in the current market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.360). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.695). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement